| 摘要 |
The present invention relates to at least one novel human GLP-1 mimetibody or agonist, or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or agonist, or specified portion or variants, GLP-1 mimetibody or agonist, or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including diabetes related therapeutic and/or diagnostic compositions, methods and devices. |
